leisure time -WSS

leisure time

author：focus 2025-10-01 15:30:40 - browse：95676

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： FDA's Woodcock to retire early next year

hotspot

knowledge

WSS

The pain doctors face in trying to build their families

An interview with Robert F. Kennedy Jr. on vaccines

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Cancer drug shortages' outsize impact on ovarian cancer patients

The pain doctors face in trying to build their families

ActiGraph execs on goal of drug approvals with digital endpoints

explore

leisure time

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Childhood cancer progress stalls for Black, Hispanic kids: Report

Sports medicine is finally prioritizing gender equality

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Psychedelics group wrestles with new pharma identity

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Medicare details structure of new drug price negotiation program

David Sabatini, ex

Medicare proposal to cover medical devices draws a mixed reaction

FDA's Woodcock to retire early next year

focus

The pain doctors face in trying to build their families

New details revealed about Purdue's marketing of OxyContin

Beware the threat of staffing cuts at the CDC

Does good food count as health care? Study aims to find out

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

hotspot

knowledge

hotspot

leisure time